肿瘤细胞治疗研究
ALL SOURCES
AI-guided CAR designs and targeted pathway modulation to enhance multi-antigen CAR T cell durability and overcome antigen escape.
综合起来，我们的研究提出了一种新一代 AI 引导的 CAR-T 策略，该策略整合基于结构的优化与细胞内调控，以改善持久性、拓宽抗原覆盖并确保持久的治疗疗效。
Quantitative Characterization of Innate and Adaptive Pharmacology of Allogeneic anti-CD20 Chimeric Antigen Receptor (CAR) Vδ1 γδ T cells using Multisc
Gamma Delta (γδ) T 细胞目前正被评估作为传统 alpha-beta (αβ) T 细胞的治疗替代方案，因其具有更优的安全性特征和增强的组织滞留特性。
The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation.
小泛素样修饰蛋白（SUMO）是泛素样蛋白超家族的一员。
Gene expression profiling of recipient immune cells induced by 7 × 19 CAR-T cell dosing in a syngeneic mouse model.
这些结果表明，7 19 CAR-T细胞能启动宿主免疫细胞的早期募集和激活，这有助于其相较于传统CAR-T细胞具有更优越的抗肿瘤活性。
Broadening anticancer spectrum by preprocessing and treatment of T- lymphocytes expressed FcγRI and monoclonal antibodies for refractory cancers.
该联合策略通过降低抗体剂量显著提升了安全性。
Prognostic Impact of the Immunoscore Based on Whole-Slide Image Analysis of CD3+ Tumor-Infiltrating Lymphocytes in Diffuse Large B-Cell Lymphoma.
在此，对104例接受R-CHOP（利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松龙）治疗的DLBCL患者，评估了基于肿瘤浸润CD3+ T细胞密度的Immunoscore的预后价值。
CAR T-cell Entry into Tumor Islets Is a Two-Step Process Dependent on IFNγ and ICAM-1.
表达嵌合抗原受体（CAR）的 T 细胞过继转移对晚期 B 细胞恶性肿瘤已显示出显著的临床疗效，但对实体瘤尚未显示出疗效。
Chimeric antigen receptor (CAR) T-cell therapy-related gastrointestinal toxicity: Histologic features and morphologic mimics.
本研究前瞻性识别了来自 3 例出现 CAR-T 细胞治疗相关 GI 毒性的患者的 5 组 GI 活检标本。
Optimizing Ex Vivo CAR-T Cell-Mediated Cytotoxicity Assay through Multimodality Imaging.
基于CAR-T细胞的疗法在治疗恶性肿瘤，尤其是液体肿瘤方面已展现出显著疗效，并且正越来越多地在实体瘤的临床试验中接受评估。
Immunotherapy and Targeted Therapies Efficacy in Thymic Epithelial Tumors: A Systematic Review.
尽管研究存在异质性，本综述表明，对于一线化疗后不适合根治性治疗的特定TET患者，ICI可能是一种治疗选择。
共 10 条
MEMBER ACCOUNT
登录成功会直接打开下一页。
